布斯皮龙和佐尔米特里普坦组合治疗动力障碍:一个随机,受控,交叉研究
Peter A LeWitt1, Glenn T Stebbins2, Kenneth Vielsted Christensen3
1Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, Michigan, USA.
概括
这项研究发现,将巴斯皮龙和佐尔米特里普坦结合在一起有效地减少了帕金森病 (PD) 动力障碍,而不会恶化运动症状. 这种组合疗法对在PD患者中治疗勒沃多巴诱导的运动障碍有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 临床前研究表明,巴斯皮龙 (5-HT1A激动剂) 和佐尔米特里普坦 (5-HT1B/1D激动剂) 的协同作用可以减少运动不良.
- 莱沃多巴诱导的动力障碍是帕金森病 (PD) 的常见和致残的运动并发症.
研究的目的:
- 为了评估buspirone和zolmitriptan的固定剂量组合的治疗潜力.
- 评估这种组合在患有勒沃多巴诱导的运动障碍的PD患者的疗效和安全性.
主要方法:
- 一个单中心,随机,安慰剂控制,双向交叉研究 (NCT02439203).
- 涉及30名PD患者,患有中度致残的峰值效应动症.
- 用布斯皮龙/佐尔米特里普坦 (10/1.25毫克每天三次) 固定剂量治疗方案七天.
主要成果:
- 与安慰剂相比,巴斯皮龙/佐尔米特里普坦显著降低了动力障碍得分 (异常非自愿运动量表) (平均差异: -4.2).
- 根据统一帕金森病评分表 (UPDRS) 第三部分 (ON) 评分,没有观察到运动功能的显著恶化 (平均差异:0.6).
- 在研究期间没有报告任何严重不良事件.
结论:
- 将巴斯皮龙/佐尔米特里普坦添加到现有的PD药物中,显著降低了动力障碍症的严重程度.
- 这种组合疗法为治疗帕金森病的动力障碍提供了潜在的新治疗策略.
- 这些发现支持buspirone/zolmitriptan作为改善PD运动并发症的可行选择,而不会影响运动控制.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Anxiolytic Drugs: Benzodiazepines and Buspirone
766
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
766
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
260
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
260


